ClinicalTrials.Veeva

Menu
C

Complete Dermatology | Sugar Land

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Relugolix
LY3471851
Lebrikizumab
RPT193
Amlitelimab
PF-07264660
PF-07275315
Upadacitinib
Dupilumab
Baricitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 19 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for...

Enrolling
Uterine Fibroids
Endometriosis
Drug: Relugolix Combination Tablet

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Placebo
Drug: Baricitinib

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participant...

Enrolling
Dermatitis Atopic
Drug: Topical calcineurin inhibitors
Drug: Amlitelimab

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and fa...

Enrolling
Alopecia Areata
Drug: Upadacitinib
Drug: Placebo

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Enrolling
Chronic Inducible Urticaria
Drug: Remibrutinib
Other: Placebo

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315

The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.

Active, not recruiting
Contraception
Drug: Relugolix Combination Therapy

Trial sponsors

M
Lilly logo
Nektar Therapeutics logo
Pfizer logo
Sumitomo Pharma logo
AbbVie logo
Merck Sharp & Dohme (MSD) logo
Novartis logo
RAPT Therapeutics logo
Sanofi logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems